Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

LIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

REVENUES:

Sales $489,664 $428,729 $1,408,603 $1,287,802

Other revenues 8,818 9,692 25,813 34,865

498,482 438,421 1,434,416 1,322,667

COSTS AND EXPENSES:

Cost of sales 121,477 82,258 312,711 251,970

Research and development 88,325 93,527 250,169 274,078

Selling, general and

administrative 222,948 186,456 631,832 527,962

Settlement reserve 7,450 369,000 7,450 425,000

Restructuring charges 1,497 - 6,973 -

In-process research and

development - - 10,000 -

441,697 731,241 1,219,135 1,479,010

INCOME (LOSS) FROM

OPERATIONS 56,785 (292,820) 215,281 (156,343)

OTHER INCOME (EXPENSE):

Interest income 4,002 8,868 15,515 23,485

Interest expense (8,831) (5,660) (25,697) (15,272)

Gain on extinguishment of

debt - 5,319 - 5,319

Gain on sale of investment - - - 5,791

Other income (expense), net (2,284) 2,493 1,488 3,747

(7,113) 11,020 (8,694) 23,070

INCOME (LOSS) BEFORE INCOME

TAXES
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  InterMune, Inc. (NASDAQ: ITMN ... quarter 2014 financial results at the close of the ... call and webcast will be hosted by InterMune at ... Interested investors and others may participate in the conference ... conference ID#21728775. A replay of the webcast and teleconference will ...
(Date:7/25/2014)... Albany, NY (PRWEB) July 26, 2014 ... Trials Review, H2, 2014" provides data on the ... This report provides elemental information and data relating ... Cerebral Stroke. , View full global Ischemic Stroke ... It includes an overview of the trial numbers ...
(Date:7/25/2014)... July 25, 2014 According to a ... Drugs Market - Global Industry Analysis, Size, Share, Growth, ... drugs market is estimated at USD 161,056.5 million in ... of 10.1% from 2014 to 2020, to reach an ... The biological drugs market is witnessing a significant growth ...
(Date:7/25/2014)... /PRNewswire-iReach/ -- Xybion Corporation, the leading provider of ... in highly regulated industries, announced today that the ... Group Conference, Xybion International Exchange, on October 21-23, ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance Fusion.  ...
Breaking Biology Technology:InterMune to Release Second Quarter Financial Results on August 6 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3
... leaders, experts and foreign ministry delegations set to be involved in ... ... Singapore (PRWEB) March 2, 2009 -- Asia-Pacific,s largest and most ... Asia 2009 (GSA 2009), will be held in Singapore from 17th ...
... LOUIS, Feb. 27 A copy of the Company,s December ... Exchange Commission, may be obtained without charge at our website ... Sigma-Aldrich Corporation, P. O. Box 14508, St. Louis, Missouri 63178. ... Life Science and High Technology ...
... CV Therapeutics, Inc. (Nasdaq: CVTX ) today ... time in response to Astellas Pharma Inc.,s announcement that ... unsolicited tender offer for all outstanding common shares of ... in cash. CV Therapeutics, board of directors, in ...
Cached Biology Technology:News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009 2News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009 3CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer 2CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer 3
(Date:7/28/2014)... DUBLIN , July 28, 2014 ... the "Biometrics Market in Latin America 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biometrics measure and analyze biological ... facial patterns, irises, eye retinas, voice patterns, and hand ... one or more stored templates. The main purpose of ...
(Date:7/28/2014)... became the first man to reach the South Pole ... an international team of scientists led by Joe McConnell ... air pollution from industrial activities arrived long before. , ... spaced locations around the Antarctic continent, including the South ... reconstruction to date of lead pollution over the Earth,s ...
(Date:7/27/2014)... DURHAM, N.C. -- Microorganisms like bacteria and fungi can ... by antibiotics or antifungal drugs. These permanent mutations were ... strains to evolve. Now a new study has shown ... targets -- known as epimutations -- to gain the ... the new mechanism was discovered in a fungus called ...
Breaking Biology News(10 mins):Biometrics Market in Latin America 2014-2018 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3
... of evolution is periodically marked by explosions in biodiversity, ... of shapes and sizes. With a new analysis of ... have discovered that these diversifications proceeded head-first. By ... around the time of two separate extinction events, scientists ...
... are fascinating plant organs they not only anchor the ... Roots live in darkness and direct the activities of the ... Charles Darwin posited in The Power of Movement of Plants ... Due to the difficulty of accessing root tissue in ...
... Mediterranean diet with large amounts of vegetables and fish gives ... studies to be published by the Sahlgrenska Academy at the ... shown that a Mediterranean diet, based on a high consumption ... products such as meat and milk, leads to better health., ...
Cached Biology News:'Head-first' diversity shown to drive vertebrate evolution 2'Head-first' diversity shown to drive vertebrate evolution 3New tool offers unprecedented access for root studies 2
Mouse monoclonal [5H9] to RAD52 ( Abpromise for all tested applications). entrezGeneID: 5893 SwissProtID: P43351...
Purified anti-LAT...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Purified anti-human CD182 (CXCR2)...
Biology Products: